• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Morgan Stanley upgrades Vir Biotechnology to ‘overweight,’ raises PT to $20

by January 9, 2025
written by January 9, 2025

Investing.com — Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an “overweight” rating, shifting from “equal-weight,” and have also increased their price target to $20 from $10. 

The analysts flagged promising preliminary data from the company’s dual-masked TCE therapies. Vir-5500, targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer, demonstrated notable safety and efficacy in early trials. 

Among heavily pretreated participants, a 58% PSA50 response rate was observed, signaling a reduction in prostate-specific antigen levels. 

Another candidate, Vir-5818, showed early signs of efficacy in colorectal cancers, with partial tumor shrinkage in 33% of the treated cases. Both drugs exhibited manageable safety profiles, with no high-grade toxicities reported.

As per Morgan Stanley, the dual-masking technology offered by Vir can enhance therapeutic tolerability and efficacy, making these treatments more acceptable to earlier stages of cancer treatment. 

Additionally, the analysts noted that the company has extended its cash runway to mid-2027, enhancing its ability to fund ongoing clinical trials and explore strategic partnerships.

This upgrade comes as Vir diversifies beyond its traditional infectious disease portfolio into oncology. 

While the company has deprioritized some programs, such as hepatitis B, the focus on innovative cancer treatments aligns with its focus on high-potential areas. 

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Saudi Arabia stocks higher at close of trade; Tadawul All Share up 0.07%
next post
“Higher for longer” rate environment could benefit Axos Financial – Needham

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Target calls price hikes a ‘very last resort’ for offsetting tariffs as sales slump
    • Consulting firm McKinsey to pay $650 million to resolve US opioid charges

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy